1.5 billion injections Zhengda Tianqing entered the fifth batch of centralized procurement!

A few days ago, the official website of the State Food and Drug Administration showed that Palonosetron Hydrochloride Hydrochloride Injection and Dasatinib Tablets of Chia Tai Tianqing Pharmaceutical Group have been approved as supplementary applications.

Data show that Palonosetron Hydrochloride Injection is a second-generation long-acting 5-HT3 receptor antagonist.

Sales of Palonosetron Injection in the Terminals of Public Medical Institutions in China in Recent Years

Source: Terminal competition landscape of China's public medical institutions

According to data from Minaiwang, in 2020, the sales of terminal Palonosetron injections in China's urban public hospitals, county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) will exceed 1.

Up to now, seven companies including Qilu Pharmaceutical (Hainan), Jiangsu Hengrui Pharmaceutical, Liaoning Haisco Pharmaceutical, and Jiangsu Osaikang Pharmaceutical have all been approved for supplementary applications.

Sales of Dasatinib Tablets in Entity Pharmacies in Chinese Cities

Source: Database of terminal competition pattern of physical pharmacies in Chinese cities

Dasatinib tablets are used for the treatment of Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia (CML) chronic phase, accelerated phase and blast phase (acute granular change and blast phase) that are resistant to or intolerant to imatinib mesylate.

At present, there are three manufacturers of Dasatinib tablets including Chia Tai Tianqing Pharmaceutical Group, Bristol-Myers Squibb and CSPC Ouyi Pharmaceutical.